Literature DB >> 23468220

Prognostic value of proliferation markers expression in breast cancer.

Natalija Dedić Plavetić1, Jasminka Jakić-Razumović, Ana Kulić, Damir Vrbanec.   

Abstract

In this study, immunohistochemical expression of five proliferation markers: Ki-67, aurora-A kinase, survivin, B-Myb and cyclin B1, was analyzed. Consecutive 215 tumor samples from breast cancer patients operated from 2002 to 2003 were analyzed using the TMA ("tissue microarray") method. The median follow-up was 95 months (from 7.8 to 107 months). Statistically significant correlations between expression levels in five proliferation markers, and correlations between some of the proliferation markers and traditional prognostic factors were found. Statistically significant prognostic influence of aurora-A kinase, survivin and B-Myb expression levels on overall and disease-free survival was found, and cyclin B1 expression level on disease-free survival. A multivariate analysis confirmed survivin and B-Myb expression as independent prognostic factors of overall (p = 0.0195; p = 0.0004) and disease-free survival (p = 0.0107 and p = 0.0205) in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468220     DOI: 10.1007/s12032-013-0523-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  65 in total

1.  Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.

Authors:  Heidi Kühling; Per Alm; Håkan Olsson; Mårten Fernö; Bo Baldetorp; Reza Parwaresch; Pierre Rudolph
Journal:  J Pathol       Date:  2003-04       Impact factor: 7.996

Review 2.  B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer.

Authors:  Arturo Sala
Journal:  Eur J Cancer       Date:  2005-09-29       Impact factor: 9.162

3.  Survivin modulates microtubule dynamics and nucleation throughout the cell cycle.

Authors:  Jack Rosa; Pedro Canovas; Ashraful Islam; Dario C Altieri; Stephen J Doxsey
Journal:  Mol Biol Cell       Date:  2006-01-11       Impact factor: 4.138

4.  Aurora-A interacts with Cyclin B1 and enhances its stability.

Authors:  Lili Qin; Tong Tong; Yongmei Song; Liyan Xue; Feiyue Fan; Qimin Zhan
Journal:  Cancer Lett       Date:  2008-11-22       Impact factor: 8.679

5.  Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.

Authors:  Maria Giselle Peters; Maria del Carmen C Vidal; Liliana Giménez; Laura Mauro; Eduardo Armanasco; Carlos Cresta; Elisa Bal de Kier Joffé; Lydia Puricelli
Journal:  Oncol Rep       Date:  2004-11       Impact factor: 3.906

6.  Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

Authors:  E Niméus-Malmström; A Koliadi; C Ahlin; M Holmqvist; L Holmberg; R-M Amini; K Jirström; F Wärnberg; C Blomqvist; M Fernö; M-L Fjällskog
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 7.  Aurora kinases as anticancer drug targets.

Authors:  Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

8.  Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.

Authors:  A Neri; D Marrelli; C Pedrazzani; S Caruso; A De Stefano; F Mariani; T Megha; G De Marco; G Corso; E Pinto; F Roviello
Journal:  Eur J Surg Oncol       Date:  2008-03-04       Impact factor: 4.424

9.  Improved grading of breast adenocarcinomas based on genomic instability.

Authors:  Ulrike Kronenwett; Sören Huwendiek; Carin Ostring; Neil Portwood; Uwe J Roblick; Yudi Pawitan; Ayodele Alaiya; Roland Sennerstam; Anders Zetterberg; Gert Auer
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

Authors:  G MacGrogan; L Mauriac; M Durand; F Bonichon; M Trojani; I de Mascarel; J M Coindre
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more
  9 in total

1.  MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer.

Authors:  Fei Ren; Lisha Wang; Xiaohan Shen; Xiuying Xiao; Zebing Liu; Ping Wei; Yiqin Wang; Peng Qi; Chen Shen; Weiqi Sheng; Xiang Du
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY.

Authors:  Ljubica Radmilović Varga; Natalija Dedić Plavetić; Paula Podolski; Davor Mijatović; Ana Kulić; Damir Vrbanec
Journal:  Acta Clin Croat       Date:  2021-03       Impact factor: 0.780

Review 3.  Localization and upregulation of survivin in cancer health disparities: a clinical perspective.

Authors:  Salma Khan; Heather Ferguson Bennit; Malyn May Asuncion Valenzuela; David Turay; Carlos J Diaz Osterman; Ron B Moyron; Grace E Esebanmen; Arjun Ashok; Nathan R Wall
Journal:  Biologics       Date:  2015-07-09

4.  Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.

Authors:  Margret Aradottir; Sigridur T Reynisdottir; Olafur A Stefansson; Jon G Jonasson; Asgerdur Sverrisdottir; Laufey Tryggvadottir; Jorunn E Eyfjord; Sigridur K Bodvarsdottir
Journal:  J Pathol Clin Res       Date:  2014-11-07

5.  Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma.

Authors:  Hui Qin; Yunyun Li; Hongyan Zhang; Feng Wang; Hongliu He; Xue Bai; Shanshan Li
Journal:  Onco Targets Ther       Date:  2019-03-08       Impact factor: 4.147

6.  AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.

Authors:  Nelson Rangel; Milena Rondon-Lagos; Laura Annaratone; Andrés Felipe Aristizábal-Pachon; Paola Cassoni; Anna Sapino; Isabella Castellano
Journal:  Cells       Date:  2020-04-24       Impact factor: 6.600

7.  Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.

Authors:  Nina Oparina; Malin C Erlandsson; Anna Fäldt Beding; Toshima Parris; Khalil Helou; Per Karlsson; Zakaria Einbeigi; Maria I Bokarewa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

Review 8.  Novel Molecular Markers for Breast Cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Biomark Cancer       Date:  2016-03-13

9.  The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.

Authors:  Audra N Iness; Jessica Felthousen; Varsha Ananthapadmanabhan; Fatmata Sesay; Siddharth Saini; Keelan Z Guiley; Seth M Rubin; Mikhail Dozmorov; Larisa Litovchick
Journal:  Oncogene       Date:  2018-09-11       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.